Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Single-blind, Randomised, Placebo-controlled, Parallel group Design Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 3032950 Administered as Intravenous Infusion (Part A) or Subcutaneous Injection (Part B) to Healthy Male Subjects

Next Previous
Trial Profile

A Phase I Single-blind, Randomised, Placebo-controlled, Parallel group Design Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 3032950 Administered as Intravenous Infusion (Part A) or Subcutaneous Injection (Part B) to Healthy Male Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 3032950 (Primary) ; BI 3032950 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 25 Sep 2023 Status changed from active, no longer recruiting to completed.
  • 22 Jun 2023 Status changed from recruiting to active, no longer recruiting.
  • 07 Feb 2023 Planned End Date changed from 31 Aug 2023 to 25 Sep 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top